Clinical Trial

Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA )

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
There is evidence to suggest that DHEA-based treatment could be beneficial to patients with asthma, yet one of the main treatments for asthma (taking glucocorticoids, a hormone that is effective in reducing inflammation), suppresses the production of DHEA. In this study, the investigators want to test and evaluate the safety of DHEA-based treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-11; most recent amendment 2026-02-25.
Trial Details
NCT Number NCT07179952
Lead Sponsor Indiana University
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Asthma
Enrollment 30 participants
Start Date 2027-01-01
Primary Completion 2028-09-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-27